Jeffrey Afrifa-Yamoah
Jeffrey Afrifa-Yamoah publishes mostly in Hematology, Epidemiology and Oncology, on topics such as Multiple and Secondary Primary Cancers, Multiple Myeloma Research and Treatments and Lymphoma Diagnosis and Treatment.
- World rank
- #6,296,396 of 7,710,434 ranked researchers
- Rank in United States
- #1,500,705 of 1,627,098
- Works
- 28
- Citations
- 15
- Citations per work
- 0.5
What does Jeffrey Afrifa-Yamoah research?
Jeffrey Afrifa-Yamoah's work is mostly in Medicine (72%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2071.9%
- Medicine2071.9%
- Everything else828.1%
- 1Hematology19% of their works
- 2Epidemiology14% of their works
- 3Oncology12% of their works
- 4Genetics10% of their works
- 5Pathology and Forensic Medicine9% of their works
- 6Public Health, Environmental and Occupational Health7% of their works
Research topics
- Multiple and Secondary Primary Cancers
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Cancer Immunotherapy and Biomarkers
Which keywords describe Jeffrey Afrifa-Yamoah's research?
The keywords of their largest research topics: Rituximab, Multiple Primary Cancers, Prognostic Factors, Second Primary Neoplasms, Diagnosis Criteria, International Myeloma Working Group, Classification and Lymphoma.
- PD-1 and PD-L1
- Myelofibrosis
- Imatinib
- Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Lymphoma
- International Myeloma Working Group
- Second Primary Neoplasms
- Multiple Primary Cancers
- Rituximab
- Prognostic Factors
- Diagnosis Criteria
- Classification
- AML
- BCR-ABL
- Genomic Aberrations
- JAK2 Mutation
- Immune Checkpoint Blockade
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 18 words, with their numbers
- Rituximab72 topics
- Multiple Primary Cancers61 topic
- Prognostic Factors62 topics
- Second Primary Neoplasms61 topic
- Diagnosis Criteria51 topic
- International Myeloma Working Group51 topic
- Classification41 topic
- Lymphoma41 topic
- AML31 topic
- Acute Myeloid Leukemia31 topic
- BCR-ABL31 topic
- Chronic Lymphocytic Leukemia31 topic
- Genomic Aberrations31 topic
- Imatinib31 topic
- JAK2 Mutation31 topic
- Myelofibrosis31 topic
- Immune Checkpoint Blockade21 topic
- PD-1 and PD-L121 topic
Where does Jeffrey Afrifa-Yamoah work?
Jeffrey Afrifa-Yamoah's main affiliation in the publication record is Trinity Health, United States.
How many publications and citations does Jeffrey Afrifa-Yamoah have?
OpenAlex counts 28 works and 15 citations for Jeffrey Afrifa-Yamoah, an h-index of 2, ranking #6,296,396 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Jeffrey Afrifa-Yamoah. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.